Cord Blood America Names Managing Director of Its New Stem Cell Company in Germany

Jun 23, 2010, 12:00 ET from Cord Blood America, Inc.

LAS VEGAS and HAMBURG, Germany, June 23 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI) (www.cordblood-america.com) is pleased to announce that Thomas Kolzau, Hamburg, Germany, an executive with a strong record of success in the medical, life sciences and bio/pharma industries, has been appointed Managing Director of Cord Blood America's 51 percent owned stellacure GmbH, the third largest cord blood banking service in Germany.

Mr. Kolzau previously served as CEO for a consulting firm which advised on the German health care system and the life sciences industry in that European nation.  He served as Head of Sales & Business Development for IBP AG, a leading company in the field of assessment, development, and application of patent-based technologies. With a managed asset volume of over 200 million euros, IBP AG is the market leader in the field of technology development funds.

Mr. Kolzau earned a diploma as a biologist at UKE Hamburg University.  He has done doctoral and post doctoral studies in oncology and innovative drug development.  He has also served as an executive with life sciences and microarray systems companies as well as companies in the bio/pharma industry.

"We are pleased that such a successful, talented executive is joining us at Cord Blood America.  We envision our new German facility as the hub to expand into the rest of Europe, where saving umbilical cord blood stem cells is becoming increasingly popular," said Matthew Schissler, co-founder and CEO.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

CONTACT:

Paul Knopick

E & E Communications

949/707-5365

pknopick@eandecommunications.com

SOURCE Cord Blood America, Inc.



RELATED LINKS

http://www.cordblood-america.com